Premarket analyst action - healthcare

|By:, SA News Editor

Health Insurance Innovations (NASDAQ:HIIQ) initiated with Buy rating and $38 (67% upside) price target at B. Riley FBR.

CymaBay Therapeutics (NASDAQ:CBAY) initiated with Outperform rating at Evercore ISI.

Summit Therapeutics (NASDAQ:SMMT) initiated with Buy rating and $33 (206% upside) price target at BTIG Research.

Premier (NASDAQ:PINC) initiated with Market Perform rating at Cowen and Company.

AveXis (NASDAQ:AVXS) initiated with Buy rating and $147 (31% upside) price target at Mizuho Securities.

Novus Therapeutics (NASDAQ:NVUS) initiated with Buy rating and $7 (124% upside) at Ascendiant.

Spark Therapeutics (NASDAQ:ONCE) initiated with Buy rating and $79 (46% upside) price target at Mizuho.

REGENXBIO (NASDAQ:RGNX) initiated with Neutral rating and $28 (5% upside) price target at Mizuho.

Audentes Therapeutics (NASDAQ:BOLD) initiated with Neutral rating and $26 (21% downside risk) price target at Mizuho.

Quest Diagnostics (NYSE:DGX) upgraded to Neutral at Credit Suisse.

Celgene (NASDAQ:CELG) upgraded to Overweight with a $105 (14% upside) price target at Barclays.

Subscribe for full text news in your inbox